Associated Papers
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
41022739 (PubMed )
Supplement: 41467_2025_63528_MOESM7_ESM.xlsx › Sheet1
Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth.
Lv FL et al.
The Journal of Biological Chemistry, 2025
Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart.
Huang S et al.
Journal of Molecular Cell Biology, 2022
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.
Ben-Cohen G et al.
Briefings in Bioinformatics, 2022
35043155 (PubMed )
Supplement: supplementary_table_s1_bbab524.xlsx › S1B._Negative_Set
Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability.
Reza MN et al.
Scientific Reports, 2021
34584144 (PubMed )
Supplement: 41598_2021_98547_MOESM1_ESM.zip › Supplementary_files-5-8-21 › Supplementary_file_4.xlsx › Sheet1
mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression.
Kon N et al.
Genes & Development, 2021
Temporal and differential regulation of KAISO-controlled transcription by phosphorylated and acetylated p53 highlights a crucial regulatory role of apoptosis.
Choi SH et al.
The Journal of Biological Chemistry, 2019
USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells.
Padmanabhan A et al.
Nature Communications, 2018
29593334 (PubMed )
Supplement: 41467_2018_3599_MOESM2_ESM.pdf
Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity.
Zheng S et al.
Cancer Research, 2017
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.
Leroy B et al.
Cancer Research, 2017
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S et al.
Oncotarget, 2016
The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain.
Laptenko O et al.
Molecular Cell, 2015
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
25372392 (PubMed )
Supplement: pone.0111694.s006.pdf
p53 requires an intact C-terminal domain for DNA binding and transactivation.
Kim H et al.
Journal of Molecular Biology, 2012
Negative regulation of p53 functions by Daxx and the involvement of MDM2.
Zhao LY et al.
The Journal of Biological Chemistry, 2004
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity.
Xirodimas DP et al.
Cell, 2004
Select a paper to view details